ConceptoMed AS is delighted to announce a new partner for the Norwegian hospital market.

We have entered into a distribution agreement with Vingmed AS granting exclusive rights for marketing, sales and distribution of the LuerJack syringes in the hospital market in Norway. 

The Vingmed Group is a Norwegian based medical company withdistribution and services of high quality medical technical products. They strive to have integrated product programs in the Nordic countries, however each company acts independently within its marketplace. 

In Norway, Vingmed AS focuses its business within the fields of cardiology, radiology, endoscopy, dialysis, intensive care, anaesthesia, general-, vascular and thoracic surgery. The product range is evaluated with respect to high quality and competitiveness. When choosing suppliers, fast and reliable capacity of delivery and a high level of innovation and continuity are factors of great importance. In addition to our high demands on the products that we represent, we aim to employ the best talents in the market and guarantee confident relations with our customers said Petter Solum, M.D., CEO of Vingmed AS. suppliers.

Visit: http://vingmed-as.no/

This distribution agreement strengthens ConceptoMed’s strategy to become strong in the home market, Norway, offering an alternative to the conventional medical syringe market worldwide.

Despite the increased focus on infection control, healthcare acquired injection related infections are still an important issue. The one-handed LuerJack system prevents accidental cross contamination, which is a real and challenge in safe healthcare delivery. The LuerJack syringe is the only syringe designed with a one-handed disconnection capability. Its integrated one-hand ’Click and Release’ function significantly reduces the risk of unintended human error. It enables a fast, safe and more efficient disconnection from the needle or any other medical attachments, and thereby reduces dramatically the risk of needlestick injuries.

Vingmed is the perfect sales, marketing and distribution partner for LuerJack in the Norwegian healthcare market. Their track record of introducing important medical innovations and integrated product programs to healthcare professionals in Norway is outstanding. The salesforce is used to solution selling and successful implementation of new products, as well as selling procedure packs, which is instrumental for LuerJack. “We really look forward to contribute to improving infection prevention and patient safety in our home market”, said Christian Mide, M.D., CEO and co-founder of ConceptoMed.

For more information, please visit www.luerjack.com and/or contact:

Christian Mide, CEO christian.mide@conceptomed.com	+47 95 100 720
Petter Solum, CEO petter.solum@vingmed-as.no	+47 901 58 368
Ann-Christine Jungmar, CCO ann-christine.jungmar@conceptomed.com	+46 708 71 46 76

ConceptoMed AS has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LuerJack Slip syringes and the first LuerJack Lock 10ml syringe.

“We are very pleased to receive FDA 510(k) market clearance for our LuerJack Slip and Lock syringes. The FDA 510(k) market clearance for LuerJack Lock 10ml represents another important milestone in our global strategy and will open up potential of establishing a commercial presence of the LuerJack in the world’s largest single healthcare market, the US. The proprietary LuerJack connection/disconnection fluid transfer technology has potential in a number of applications, ranging from all syringes, blood gas syringes, pre-filled syringes and control syringes to connectors in general”, said Christian Mide, M.D., CEO and co-founder of ConceptoMed.

LuerJack – more than a syringe!

With continued global focus on reducing Healthcare Associated Infections (HAI), a recent study conducted by Research Institutes of Sweden (RISE) documents that LuerJack may play an important role in reducing the rate of contaminated injected medication in clinical settings.

LuerJack addresses human factor risk mitigation in aseptic procedures when handling medical connections, cannula hubs, spikes etc. – simply by its one-handed, non-twisting disconnection capability. The one-handed disconnection makes LuerJack user-friendly – just ”click and release” without twisting off.

Safety through simplicity!

By its design, the one-handed disconnecting syringe LuerJack supports an aseptic non-touch technique. The RISE study documents a 46% reduced contamination of injected medication, compared to today’s conventional available syringe designs. This may significantly reduce bloodstream infections.

A key contribution to a next-generation medical syringes and connectors may become the development away from using two hands during disconnections – enabling ergonomic, safe, non-twisting disconnection and aseptic handling of needle-less ports, needles, caps and any other connected devices.

On the 14^th of February 2017, the Chinese Patent and Trademark office issued an official document granting the Chinese patent for LuerJack.

The innovative LuerJack syringe is unique through the very simple one-handed operated disconnection function. Based on the leverage effect, the ‘Click and Release’ feature performs fast, safe and more efficient one-handed disconnections from needles and any other medical luer connections, and thereby offer prevention from needlestick injuries. Using only one hand safeguards aseptic technique and could become a vital part of the on-going struggle to reduce the occurrence of healthcare acquired infections.

ConceptoMed’s strategy to protect our intellectual property rights (IPR) remains unchanged and strong. Along with other markets already protected, such as Europe, the US, Australia and Mexico, protection in Asia is now following. The LuerJack^® is firmly protected by 8 patent families and > 60 patent applications (granted and pending).

Obtaining proper IPR protection in China is fundamental to our planned global journey towards new market entries.

‘ConceptoMed is serving the global market with innovative product categories and unique proprietary technology. These additional issued patent for LuerJack is another instrumental milestone for ConceptoMed. The global growth and reach of the LuerJack concept will now be a step closer to access patients and healthcare workers worldwide – also beyond Europe.’, said Christian Mide, M.D., CEO and founder of ConceptoMed.

Background

The 6% taper friction fit (luer) connection is the most common connector type used in medical settings. Tapered fittings ensure tight connections by allowing female hubs to bond with male tips by friction fit. The simple design creates a strong hold. It was invented in the 1890’s and has been used predominantly in medical settings for over a century. However, both traditional luer slip and luer lock applications are disengaged using two hands for the operation – with fingers in close proximity with critical aseptic parts and sharp objects of medical procedures.

ConceptoMed AS received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first size of the Luer-Jack^® syringe.

“I am very pleased to receive FDA 510(k) market clearance for our first size of the Luer-Jack^® Slip syringe. The FDA 510(k) market clearance represents another important milestone in our global company strategy and will open up potential of establishing a commercial presence of the Luer-Jack^® in the world’s largest single US healthcare market”, said Christian Mide, M.D., CEO and founder of ConceptoMed.

About Luer-Jack^®

Luer-Jack^® is a user-friendly syringe, which will become an important contribution to procedure quality and aseptic procedures when handling medical connections – simply by its one-handed disconnection capability. Luer-Jack^® is delivered in a simple to use and uniquely designed packaging – the Steri-Tilt^™.

Health authorities and medical professionals now have the option of implementing a medical device with an integrated and user-friendly one-handed aseptic disconnection technique as part of the medical device itself.

A key element of a next-generation medical syringe could become the development away from using two hands during disconnections.

Luer-Jack^® Slip syringes are already CE marked and sold by distributors in Europe.

For more information, please visit www.luerjack.com and/or contact:

Christian Mide, CEO – christian.mide@conceptomed.com	+47 95 100 720
Martinsen, Director QA & Reg. – marit.martinsen@conceptomed.com	+47 905 146 90
Ann-Christine Jungmar, CCO – ann-christine.jungmar@conceptomed.com	+46 708 71 46 76

In December 2016, ConceptoMed have entered into important collaboration agreements with suppliers of sterilization services and logistics & warehousing services to secure the global strategy for ConceptoMed and Luer-Jack.

Sterigenics International LLC is a global leader in contract sterilization services, operating 47 facilities in 13 countries. Whilst being manufactured in Sweden, Luer-Jack is sterilized in Denmark, and Sterigenics has processing capacity to support further expansion plans for Luer-Jack into the global healthcare market. Sterigenics offer safe and reliable sterilization services with cutting-edge technologies.

‘I am very pleased to focus on the growth phase together with a great global player in the field of sterilization services. The agreement with Sterigenics enables ConceptoMed to secure the increasing need for sterilization services for Luer-Jack, and represents another important milestone for ConceptoMed – for the further reach of Luer-Jack into existing and new markets – and ultimately for patients and healthcare workers worldwide’, said Christian Mide, M.D., CEO and founder of ConceptoMed.

‘It is very exciting to continue a fruitful cooperation with the team from ConceptoMed. We are looking forward to supporting the global growth of the innovative Luer-Jack technology‘, said Kim Harboe, CEO of Sterigenics Denmark.

In December 2016, ConceptoMed also entered into a collaboration with DSV Logistics to secure the supply chain needs – such as warehousing and transportation to a global market. DSV are a leading global supplier for transport and healthcare logistics services by air, sea and road.

On the 28^th of October 2016, ConceptoMed and AB Euroform MediPharm entered into an agreement for high-volume capacity manufacturing for Luer-Jack. Euroform MediPharm is a ISO 13485 certified long-term partner within development and production of polymer products for world class customers in Pharmaceutical and Medical Technology industries. Euroform MediPharm operates a medical plant Cleanroom class 8 facilities in Motala, Sweden. AB Euroform also operates high-tech industrial injection molding plants in Motala and Tranås in Sweden.

Wind will power the manufacturing of Luer-Jack

AB Euroform is owned by Vätterleden Invest, which among other businesses, also owns and operates a wind-mill plant in the southern part of Sweden. The Vätterleden owned wind-power plant produces more electrical power than the total aggregate power consumption for all manufacturing operations in AB Euroform.

‘AB Euroform MediPharm have supported the early phase manufacturing for Luer-Jack. I am very pleased to focus on our growth phase together with a great company and great people from Sweden. The agreement with AB Euroform MediPharm enables ConceptoMed to secure deliveries to a growing customer base for Luer-Jack. It is an important milestone for ConceptoMed, for the global growth of the Luer-Jack concept – and ultimately for patients and healthcare workers worldwide – also beyond Europe’, said Christian Mide, M.D., CEO and founder of ConceptoMed.

‘It is very exciting to continue a fruitful cooperation with the innovative team of ConceptoMed. Now we are thrilled to take our cooperation into high volume production and an even closer cooperation‘, said Håkan Jimstad, CEO and partner of AB Euroform.

ConceptoMed AS is a ISO 13485 certified, ambitions medtech company serving the global market with innovative product categories and unique proprietary technology. We create smart medtech systems that empower healthcare professionals and improve patient care. Excellence through simplicity is our code. We are brave, curious and dedicated. We simply care.

Based in Norway, the team is continuously meeting milestones and expanding its activities for international growth. For more information on the company and career opportunities, see www.conceptomed.com and www.luerjack.com. Follow us on MyNewsdesk and LinkedIn.

Euroform MediPharm is a ISO 13485 certified Swedish long-term partner within development and production of polymer products for world class customers in Pharmaceutical and Medical Technology industries. Many years of experience within highly qualified polymer system solutions development has formed the solid base of peak competence and quality awareness that is seen in everything we do today.

Luer-Jack^® is a registered trademark owned by ConceptoMed AS. The Luer-Jack^® technology is widely patent protected throughout the world, currently with almost 50 patents (granted and pending) from 8 patent families.

ConceptoMed is proud to announce that it successfully passed the ISO 13485 quality assurance audit, and was issued the international ISO 13485 certificate by SP, our Notified Body.

The ISO 13485 standard specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices that consistently meet customer and regulatory requirements applicable to medical devices, certifying that the organization’s Quality Management System for Medical Devices responds to this rigorous standard for the design, development, and production of medical devices.

‘Achieving the International Organization for Standardization certification for our quality management system reflects our commitment to the development of innovative, safe and effective products for the global market’ commented Christian Mide, CEO of ConceptoMed.

Marit Martinsen, Head of Regulatory Affairs and Quality Assurance in ConceptoMed, stated that ‘the ISO 13485 certification illustrates ConceptoMeds strong commitment to quality and our ability to reach milestones crucial to the regulatory processes required for worldwide medical device commercialization’.

‘Obtaining the ISO 13485 certification is a testament to the professionalism, the rigor, and team spirit that prevails within our company’ indicated Christian Mide. ‘The achievement of this important objective is a key step toward the marketing and further development of the company’s products on the healthcare markets over the course of the coming years.’

On the 31^st of August 2016, the European Patent Office issued an official document granting the European patent for Luer-Jack.

IP Australia, the Australian Government agency that administers intellectual property (IP) rights and legislation relating to patents, issued an official document granting the Australian patent for Luer-Jack – also on the 31^st of August 2016.

These two patents are an important part of the families of similar granted and filed applications in all important markets world wide, including the granted patent for the USA, and are a fundamental member of the Luer-Jack patent family.

The innovative Luer-Jack syringe is unique through the very simple one-handed operated disconnection function. Based on the leverage effect, the ‘Click and Release’ feature performs faster, safer and more efficient one-handed disconnections from needles and any other medical luer connections, and thereby offer prevention from needlestick injuries. Using only one hand safeguards aseptic technique and could become a vital part of the on-going struggle to reduce the occurrence of hospital-acquired-infections.

‘ConceptoMed is serving the global market with innovative product categories and unique proprietary technology. These issued patents for Luer-Jack is an important milestone for ConceptoMed, for the global growth of the Luer-Jack concept – and ultimately for patient and healthcare worker worldwide – also beyond Europe. We intend to validate the EPO patent across Europe’, said Christian Mide, M.D., CEO and founder of ConceptoMed.

ConceptoMed AS is a rising medtech star serving the global market with innovative product categories and unique proprietary technology. We create smart medtech systems that empower healthcare professionals and improve patient care. Excellence through simplicity is our code. We are brave, curious and dedicated. We simply care.

Based in Norway, the team is continuously meeting milestones and expanding its activities for international growth. For more information on the company and career opportunities, see www.conceptomed.com and www.luerjack.com. Follow us on MyNewsdesk and LinkedIn.

Luer-Jack^® is a registered trademark owned by ConceptoMed AS. The Luer-Jack^® technology is widely patent protected throughout the world, currently with almost 50 patents (granted and pending) from 8 patent families.

We are proud to announce that ConceptoMed has been named in the Disrupt 100 – a bi-annual Tällt Ventures publication celebrating the businesses with the most potential to influence, change or create new global markets.

The report tracks the world’s most disruptive businesses, compiled and curated by the world’s leading entrepreneurs, investors and business people.

We were selected from over 1 million global startups and corporate ventures, and judged by global brands including Astra Zeneca, KPMG, IBM and Silicon Valley Bank, tech accelerators Microsoft Ventures, Mass Challenge and WAYRA and entrepreneurs Emma Sinclair, Tom Goodwin and Bill Liao.

Matt Connolly, Managing Director, Disrupt 100, said: ‘Entire industries are being disrupted by new, often well-funded startups that are able to quickly scale and displace long-established companies. The Disrupt 100 champions those businesses who are rethinking todays products, services, technologies and business models to open new markets and create new demand.’

ConceptoMed’s key product, the innovative Luer-Jack syringe, is unique through the very simple one-hand operated disconnection function. Based on the leverage effect, the ‘Click and Release’ feature performs faster, safer and more efficient one-hand disconnections from needles and any other medical luer connections, and thereby reduces the risk of needlestick injuries. Using only one hand safeguards aseptic technique and could become a vital part of the on-going struggle to reduce the occurrence of hospital-acquired-infections.

‘We are proud and humbled to be selected as the only Nordic company recognized by this index. The great potential of the innovative Luer-Jack syringe is not new to us, as healthcare professionals throughout Europe are now starting to use it, however, this is the first time we have been independently celebrated by a global index’, said Christian Mide, M.D., CEO and founder of ConceptoMed.

‘The simplicity of Luer-Jack will make a large footprint in the medical workplace and increase quality of care. From a business standpoint, strong IPR and very low co-innovation risks come from full compatibility of the Luer-Jack technology across existing medical connection standards’, said Mide.

Details on the Disrupt 100, judges, themes and more can be found at www.disrupt100.com

On the 10^th of May 2016, the United States Patent and Trademark office issued an official document granting the US patent for Luer-Jack. The US Luer-Jack patent is an important part of the families of similar filed applications in all important markets world wide, and is a fundamental member of the Luer-Jack patent family.

The innovative Luer-Jack syringe is unique through the very simple one-hand operated disconnection function. Based on the leverage effect, the ‘Click and Release’ feature performs faster, safer and more efficient one-hand disconnections from needles and any other medical luer connections, and thereby reduces the risk of needlestick injuries. Using only one hand safeguards aseptic technique and could become a vital part of the on-going struggle to reduce the occurrence of hospital-acquired-infections.

US market entry – Luer-Jack

The US patent protection for Luer-Jack will further fuel the market introduction of Luer-Jack worldwide. Obtaining proper IPR protection in USA is fundamental to our planned US market entry.

‘ConceptoMed is serving the global market with innovative product categories and unique proprietary technology. This first US issued patent for Luer-Jack is an important milestone for ConceptoMed, for the global growth of the Luer-Jack concept – and ultimately for patient and healthcare worker safety in a growing and more complex world’, says Christian Mide, M.D., CEO and founder of ConceptoMed.

Background

The 6% taper friction fit (luer) connection is the most common connector type used in medical settings. Tapered fittings ensure tight connections by allowing female hubs to bond with male tips by friction fit. The simple design creates a strong hold. It was invented in the 1890’s and has been used predominantly in medical settings for over a century. However, both traditional luer slip and luer lock applications are disengaged using two hands for the operation – with fingers in close proximity with critical aseptic parts and sharp objects of medical procedures.